NCT07480863 2026-03-18
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT07448324 2026-03-04
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06583837 2026-02-27
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Phase 2 Active not recruiting
NCT07272499 2025-12-09
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Ruijin Hospital
Phase 2 Recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07247383 2025-11-25
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT07208981 2025-10-06
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07199296 2025-09-30
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Phase 2 Recruiting
NCT06700798 2025-06-17
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06530511 2025-02-04
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06793189 2025-01-27
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06647940 2024-10-22
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Sun Yat-sen University
Phase 2 Recruiting
NCT06566807 2024-08-22
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2 Recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06513234 2024-07-22
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06454968 2024-06-18
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05978739 2023-10-25
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Phase 2 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04989621 2022-03-24
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Unknown
NCT05076097 2021-11-11
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05014100 2021-08-27
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Phase 2 Unknown